Substituted [1,2,4]triazolo[1,5-a]pyrazines as LSD1 inhibitors
US10968221B2 · kind B2 · utility
5Cited by
39References
10Claims
0Family size
Assignee
Inventors
Key dates
| Filing date | Oct 3, 2019 |
| Grant date | Apr 6, 2021 |
| Priority date | — |
| Expiry date | Oct 3, 2039 |
Classification
- Technology area (CPC C)Chemistry; Metallurgy
- CPC primaryC07D487/04
- WIPO fieldOrganic fine chemistry
- WIPO sectorChemistry
Abstract
The present invention is directed to [1,2,4]triazolo[1,5-a]pyridine and [1,2,4]triazolo[1,5-a]pyrazine derivatives of Formula IIa, or a pharmaceutically acceptable salt thereof, which are LSD1 inhibitors useful in the treatment of diseases such as cancer.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.